Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the stock market closed today ? Holiday ? Lol
BioCorRx to Present at the Sidoti & Company Spring 2017 Convention in NYC
ANAHEIM, CA – (Uptick Newswire – March 15, 2017) – BioCorRx Inc. (OTC: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, announced today that it will be presenting at the Sidoti & Company Spring 2017 Convention on Wednesday, March 29th at 8:40 AM ET at the New York Marriott Marquis in Times Square. Brady Granier, President and CEO, and Lourdes Felix, CFO and COO, will be presenting and holding one-on-one meetings with investors throughout the day.
About BioCorRx
BioCorRx Inc. (OTC: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s). For more information on BICX, visit www.BioCorRx.com.
About Sidoti & Company
Sidoti & Company, LLC is Wall Street’s preeminent provider of equity research generally focused on companies with market capitalizations of under $3 billion. We cover over 250 companies across a range of industries. The companies covered by our traditional research typically have a history of profitability, maintain strong balance sheets, and tend to have limited, if any, coverage by other Wall Street firms.
We are a broker-dealer registered with the SEC and a FINRA member firm. We provide a broad range of securities-related services. In addition to our high-quality research, our sales and trading services are distinguished by prompt execution, a competitive commission structure and access to smart order routing that utilizes all available sources of liquidity. From time to time, we are invited to participate as an underwriter, dealer, placement agent or initial purchaser in securities offerings for issuers for which we provide research coverage. Given our knowledge of the companies we cover, we believe that we are able to contribute to these capital-raising transactions. We also assist our issuers with stock repurchase programs, block trades and organized (Rule 10b5-1) trading plans.
For those interested in attending, please contact Caitlin Adams at conference@sidoti.com or visit http://www.sidoti.com/events/ for more information.
Contact:
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
10k soon ?
well !!! BIG News just around the Corner
Another interesting post /article mentioning BICX :)
America's War on Drugs
GuruFocus.comMarch 7, 2017
- By Alyangka Francheska Manalo
President Donald Trump described them as America's "forgotten people," the less-educated white, middle-aged Americans. This group of individuals, together with the baby boomers and the so-called Generation X, are among the most vulnerable to heroin and prescription drug abuse. Several studies indicate that the number of drug overdose deaths among baby boomers, Generation X and less-educated white Americans has jumped in recent years.
Warning! GuruFocus has detected 7 Warning Signs with BICX. Click here to check it out.
BICX 15-Year Financial Data
The intrinsic value of BICX
Peter Lynch Chart of BICX
Data released by the Centers for Disease Control and Prevention (CDC) in late February showed that the age-adjusted rate of drug overdose deaths in the U.S. in 2015 was more than 2.5 times the rate in 1999. The CDC claimed that the spike in the number of drug overdose deaths was tied in to the drop in the price of heroin along with easier access to prescription drugs.
In 1999, the rate of drug overdose was estimated at 6.1 per 100,000. It jumped to 16.3 per 100,000 in 2015 or an increase of 5.5% annually. From 1999 to 2006, the number increased by 10% and then another 3% from 2006 to 2013 before jumping again by 9% per year from 2013 to 2015 as shown in government data.
"The pattern of drugs involved in drug overdose deaths also has changed in recent years," according to an official in the CDC report. "In 2010, 29% of drug overdose deaths involved natural and semisynthetic opioids and 12% involved methadone. In 2015, the percentage of drug overdose deaths involving these drugs decreased to 24% and 6%. In contrast, drug overdose deaths involving heroin increased from 8% in 2010 to 25% in 2015. Increases were also seen in drug overdose deaths involving synthetic opioids other than methadone, from 8% in 2010 to 18% in 2015."
Brady Granier, president, CEO and director of BioCorRx Inc. (BICX) expressed concern over the growing drug abuse problem in the U.S. He agrees with the government's opinion that drug overdose deaths is a major public health burden. The CDC reported that the total number of drug overdose deaths totaled 47,055 in 2014.
Granier commented, "The best way to combat this problem is through prevention, but this will take a collaborative effort between parents, educators, governments, not for profits, law enforcement agencies and more. Then on the other side, there's treatment and recovery. Treatment options are evolving to address that side of the problem especially in the field of medication-assisted treatment. We are seeing some potentially very effective new tools on the horizon that can help people more efficiently in the areas detox and relapse prevention."
Pain medication now cheaper than other illegal drugs
The drop in the price of pain medications is one of the leading causes why many Americans are misusing the drug and becoming drug addicts, according to the CDC report.
"Since 1999, the amount of prescription opioids sold in the U.S. nearly quadrupled yet there has not been an overall change in the amount of pain that Americans report," according to the CDC. They also said that statistically, the number of deaths from prescription opioids has risen more than 400% over the last 15 years. This includes abuse of medications like oxycodone, hydrocodone and methadone.
A similar study by researchers at the Princeton University has confirmed that the so-called forgotten people of America are more susceptible to drug overdose deaths due to drug and alcohol poisonings, suicide and chronic liver diseases and cirrhosis.
The Princeton study concluded, "Those with less education saw the most marked increases. Rising midlife mortality rates of white non-Hispanics were paralleled by increases in midlife morbidity."
America's 'War on Drugs'
The year 2016 was a banner year for the U.S. Coast Guard's fight against drug trafficking with a record illegal drug haul.
The Coast Guard seized more than 416,000 pounds of cocaine with a street value estimated at $5.6 billion by the end of October 2016. The catch was the largest made by the Coast Guard in a single year of its history, covering 263 operations spanning the Caribbean, the Gulf of Mexico and the eastern Pacific Ocean.
That year, the Coast Guard also arrested 585 suspected drug smugglers, 465 of whom were repatriated to the U.S. mainland to face charges.
However, America's "War on Drugs" netted an estimated 1.25 million individuals arrested in the U.S. in 2015 for possession of illegal drugs. The war on drugs also resulted in unparalleled hostility and instability in drug-producing nations including Mexico, Colombia, etc. Sadly, illegal drugs still proliferate the streets despite the billions of dollars spent by the federal government in the fight against illegal drugs.
Miracle cures?
The stigma associated with drug addiction is preventing most from seeking treatment. A study by the National Survey on Drug Use and Health has found that only 14% of drug dependents will seek treatment. A majority of drug addicts find it difficult to accept that they are addicted to an illegal substance which is typically the first step in the treatment process.
Researchers said that the stigma attached to being labeled a drug addict has a profound impact in the fight against addiction as it prevents treatment resources from reaching many people who need them, and it discourages drug dependent individuals from seeking treatment at all.
However, Granier said there are several programs available to rehabilitate those suffering from addiction while preventing them from relapsing. BioCoRrx offers its BioCorRx(R) Recovery Program, a non-addictive, medication-assisted treatment (MAT) program used to treat both alcohol and opioid addictions to independent treatment providers across the U.S..
The program uses naltrexone in an implantable form that can block cravings and prevent relapse for several months while the patient goes through the proprietary counseling program that was written by addiction experts specifically for those receiving long term naltrexone treatment. Naltrexone is an opioid antagonist that blocks some of the effects of alcohol and opioids and has been FDA approved in the oral and injectable form for many years. The program also includes 12 months of peer recovery support to add another layer of support for the patient and family while also tracking results using an algorithmic software program.
Big pharmaceutical companies - Insys Therapeutics Inc. (INSY), Pfizer Inc. (PFE), Amphastar Pharmaceuticals Inc. (AMPH), Mylan NV (MYL), Opiant Technologies Inc. (OPNT), Adapt Pharma Ltd., Kaleo Pharmaceuticals and Alkermes (ALKS) - are also offering their own solutions to the drug menace.
One of the first-line treatments for opioid abuse includes Reckitt Benckiser Group's (MEX:RB N) buprenorphine, which is being marketed under the Suboxone brand name. But Suboxone is facing controversies over alleged illegal trade practice and the drug itself is suspected of causing addiction amongst its patients.
Another first-line treatment is naloxone, sold under the brand name Narcan. Narcan is said to be an effective treatment to reverse opioid overdose if treatment is administered in time. However, the price of Narcan has spiked tremendously over the past month making the drug very expensive.
A third option is naltrexone, a nonaddictive medication that is found to be an effective medication in the fight against opioid abuse, as well as alcoholism. Alkermes, a $8.39 billion pharmaceutical company, is currently selling naltrexone under its Vivitrol brand.
Granier added that BioCoRrx is in the preclinical stage of developing its own injectable naltrexone. He said, "BICX101 is being developed to provide another option to patients and doctors in the fight against addiction. Our goal is to deliver a product in a much smaller volume, with a smaller needle, and therefore presumably, less discomfort." He added that the product should not require refrigeration and may also be able to be given subcutaneously instead of in the buttocks.
Number of drug overdose deaths to decline
While the statistics on the drug overdose deaths is a cause for alarm, health authorities and researchers are predicting that the volume of drug overdoses will decline soon. They cited better law enforcement practices and more effective monitoring of prescription drugs should help reduce the drug overdose cases and eventually the number of deaths associated with it.
Scientists at Columbia University's Mailman School of Public Health estimated that the number of deaths from drug overdose will peak at 50,000 this year declining to "a nonepidemic state" of 6,000 deaths by 2035.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I have no business relationship with any company whose stock is mentioned in this article.
Start a free seven-day trial of Premium Membership to GuruFocus.
This article first appeared on GuruFocus.
Warning! GuruFocus has detected 7 Warning Signs with BICX. Click here to check it out.
BICX 15-Year Financial Data
The intrinsic value of BICX
Peter Lynch Chart of BICX
For all BICX newbies !!
IMO !! Today's trading is very healthy trend after yesterday's good trading day .
filtering out short term hands , pulling back a little ...
Means the uptrend is real / solid and not a P&D scenario ..
GOOOO BICX
well !! whatever happens in the next 9 minutes of trading ... IT WAS A GOOD DAY :)
$1+ PPS is very realistic for that company !
wake up guys . here we go again
If the trend continued ! Won't be surprised to 0.20 some time during the day !!! GOOOO BICX
Any second now ....!!!!! 0.10+
President Trump Vowed to Solve the Opioid Crisis. He Needs to Fix This Problem First
Sean Gregory,
Alexandra Sifferlin
Feb 24, 2017
During a freewheeling recent press conference, President Trump declared that America was “drug-infested” country. “Drugs,” Trump said, “are becoming cheaper than candy bars.”
What the President failed to mention: the price of one lifesaving medication—naloxone—is more expensive than caviar.
Throughout the 2016 presidential campaign, Trump promised to solve America’s opioid crisis, which claimed 33,000 lives in 2015—the most deaths in a single year in U.S. history, according to recent federal statistics. Trump's plan to combat the epidemic included widespread access to naloxone, a drug that can reverse the effects of an opioid overdose. But as the need for the drug has grown, it has become increasingly expensive and hard to get for many addicts and the front line workers who try to help them.
"All the politicians, Obama, Trump, everyone says, 'We're going to solve it'," says Gordon Merry, director of West Virginia's Cabell County EMS, which serves Huntington, a city that saw 26 opioid overdoses over four hours last August. "I haven't seen anything that has changed."
How Doctors Are Fueling the Opioid Epidemic
Meanwhile, the price of naloxone is soaring. Evzio, a form of naloxone manufactured by Kaléo that's administered through auto-injection, rose from $575 per package in 2014 to a whopping $4,100 in 2016. Another version of the drug, made by Hospira, has risen from from $9.20 for 10 vials in in 2005 to $158.30 in 2014, according to Truven Health Analytics. The price of the naloxone nasal spray Narcan has remained stable—around $125 for a two-pack—since it was approved by the FDA in 2015.
"The best word for what's happening now," says Paul Ginsburg, director of the Center for Health Policy at the Brookings Institution, "is profiteering."
Naloxone price hikes parallel a spike in demand for the drug that's fueled by the opioid epidemic, stretching government budgets—the drug is often administered by first responders—while creating a robust market for the drug.
In late November, Dr. Leana Wen, Baltimore City's Health Commissioner , and 10 other health officials wrote a letter to President Trump asking the new administration to prioritize public health, specifically solutions to the opioid epidemic. “In the campaign, President Trump talked about the problems of drug addiction,” says Wen. “We hope that this will not just be rhetoric but resources will be devoted to this issue too.” So far Wen and her colleagues haven’t received a response.
Experts attribute the rising naloxone prices to a combination of soaring need, drug-industry consolidation and an onerous FDA-approval process, which can stifle competition. Critics contend that price gouging may also be at play.
Kaléo CEO Spencer Williamson says Evzio's list price of $4,100 "is not a true net price to anyone…due to numerous discounts and rebates that are negotiated in the supply chain." Most patients with insurance pay nothing out of pocket, says Williamson, while uninsured patients with household incomes of less than $100,000 can also access Evzio free of charge.
Kaléo says it also offers product grants to some nonprofits and government agencies that demonstrate a need for the drug. For instance, Kaléo has granted 2,200 kits to the Cabell-Huntington Health Department, where the overdose death rate is nearly 10 times the national average. "The more naloxone there is, the more lives will be saved," says Dr. Michael Kilkenny, physician director of the Cabell-Huntington Health Department. "I have to admit, if we didn't get the grant, we wouldn't have the drug. We don't have the finances."
Yet even beneficiaries of naloxone grants acknowledge that demand outstrips affordable supply. In Palm Beach County, Fla., for instance, the Fire and Rescue department spent nearly $205,400 on naloxone in 2016, compared with $57,500 in 2015.
In Baltimore, first responders are facing similar constraints. “We have to decide who is the most likely to die and make a guess on which patients we distribute naloxone to,” says Wen, the health commissioner, adding that the price they pay for naloxone more than doubled over the course of just a few years. "It doesn’t make sense that at a time of great demand this medication is being priced out of our reach.”
In Newtown, Ohio, police chief Tom Synan says the opioid epidemic in his community is worsening. The county averages up to 70 overdoses a week. “That’s our new normal,” he says. Synan, who serves on the Hamilton County Heroin Coalition steering committee, says his officers use the naloxone nasal spray Narcan, and the department has not been hit with major cost increases. But the overall trend is disconcerting. “These are life and death situations," says Synan.
If his earlier promises hold true, Trump will eventually train his lens on drug companies—and drug prices. A White House spokesperson says the administration is extending grant programs to help get naloxone in the hands of first responders, has encouraged Medicaid programs to include naloxone access for low-income people, and has made sure Veterans Affairs programs offer naloxone for eligible veterans.
Still, some say more drastic action will be necessary. Ohio has already taken action: in November the state reached an agreement with Adapt Pharma, the manufacturer of Narcan, to freeze the price of the naloxone nasal spray for Ohio law enforcement, first responders, state and local government agencies, and community-based organizations for a year. These entities can buy 48 or more Narcan units for $75 each, a 40% discount from the $125 wholesale price.
"It's hard to justify the price increases you see on purely economic grounds," says Darius Lakdawalla, an economist and professor of pharmaceutical development and regulatory innovation at the University of Southern California. "The case is pretty strong for government interference."
Especially when lives are at stake. Laurie Fugitt, co-founder of Georgia Overdose Prevention, a volunteer group, hopscotches across the state teaching people how to administer naloxone to themselves or their loved ones. She equates naloxone to a fire extinguisher. You never want anyone to use it. But it should be there just in case.
"A lot of people have no idea that there's even an antidote for an opioid overdose," says Fugitt. "Back in the day, a vial of naloxone cost a couple of bucks. Now, everybody is trying to get their piece of the pie."
With reporting by Zeke J. Miller
What's happening pip ? I am not complaining one bit :)
194K Buy just went through :)
BioCorRx Provides Preclinical Study Update on BICX101 Development
Webcast Available at www.BioCorRx.com
ANAHEIM, CA, February 23, 2017 -- BioCorRx Inc. (OTC: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today provided an update on the preclinical development of BICX101, a new sustained release injectable naltrexone product for the treatment of substance abuse addiction, via a webcast that is available on the News & Media section (“Presentation” subpage) of the Company’s website: www.BioCorRx.com.
Brady Granier, President, CEO and Director, stated, "We’re very excited about the preclinical studies thus far.” He further stated that the company anticipates submitting a request for a Pre-IND meeting with the FDA sometime in the middle of March with the actual meeting anticipated to take place within 60 days from that request.
Dr. Balbir S. Brar, VP of Drug Development, commented, “We have screened a number of formulations that were produced by TheraKine and these formulations were tested in two phases of preclinical studies.” He added, “We have selected a lead formulation which is very promising and will be tested in a number of variations in additional studies to be started very shortly. So far, the results are consistent with our goals.” Brar also mentioned that the company hopes to complete the preclinical studies in 5 to 6 weeks and gain clearance for a 505(b)(2) ‘fast-track’ regulatory pathway which can shorten or even eliminate phases of the approval process. Dr. Brar provided a more detailed update on the Company’s preclinical and regulatory activities in the webcast.
Dr. David Gastfriend, Medical Consultant to BioCorRx stated, “There is a market that has emerged. It is being developed and this desire to use injectable naltrexone has become established throughout the country. An improved formulation is a valuable addition to the medical armamentarium.” In the webcast, Dr. Gastfriend discusses a number of additional anticipated benefits of BICX101 over the current approved products on the market.
About BioCorRx
BioCorRx Inc. (OTC: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
bicx@crescendo-ir.com
All Stocks mentioned in Article has a PPS between $9 & $33 Except BICX ? Any explanation why ?? PIP?
Some good buys @0.0719 ....150K just went through ...hmmmmmm !!!!
Not sure what to expect anymore .
One day someone is selling big and the next someone is buying big ????? confused
BioCorRx Announces the Appointment of Dr. Balbir S. Brar as VP of Drug Development
3 hours ago
ANAHEIM, CA / ACCESSWIRE / February 21, 2017 / BioCorRx Inc. (OTC PINK: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Dr. Balbir S. Brar has been appointed VP of Drug Development for the BioCorRx Pharmaceuticals subsidiary. Previously, Dr. Brar served as lead drug development study design consultant for the BioCorRx Pharmaceuticals subsidiary.
Dr. Brar has over 25 years of experience in drug and device development, including worldwide regulatory submissions for over 50 INDs, 510(k)s and 505(b)(2)s, as well as approval of 8 NDAs for drugs currently on the market. Dr. Brar's experience includes working with major pharmaceutical companies such as Lederle/Wyeth, where he was instrumental in the development of Azmacort for asthma, as well as topical Aristocort. At GlaxoSmithKline, as Director of Drug Safety, Dr. Brar participated in the development of Tazarotene. At Allergan, as VP of Drug Safety, he made major contributions towards the development, regulatory submission, and approval of Botox, Alphagan, Lumigan, Restasis, Ofloxacin, Azelex, and Avage.
For the past 10 years Dr. Brar has played a leadership role for several early stage biotechnology companies in the fields of nephropathy, oncology, ophthalmology, dermatology, pain, and cardiology. During this time, Dr. Brar variously served on the Board of Directors, and acted as President, EVP R&D, and Chief Technology Officer. Dr. Brar has a Ph.D. in Toxicology/Pathology from Rutgers University and D.V.M. from a university in India with finance training from Harvard Business School.
Brady Granier, President, CEO and Director, stated, "In the short time since joining our organization, Dr. Brar's contributions have been quite significant and I am very pleased to announce his new role as VP of Drug Development. It speaks to how much our team has accomplished over the last year that a small company like ours was able to attract an expert of this caliber. We believe Dr. Brar's hiring adds tremendous value and validation to what we have been developing. Dr. Brar brings extensive experience and relationships that we believe will help to accelerate the development and regulatory pathway for our current formulations, as well as potentially future ones. Our plan is to seek 505(b)(2) 'fast-track' approval for one of our products, and we look forward to providing additional updates in the near future."
Dr. Brar, VP of Drug Development, commented, "I am very excited to join the team at BioCorRx in a more formal role. Over the last several months that I have worked closely with the team at BioCorRx, I have witnessed their dedication and expert knowledge in the field of addiction treatment. I believe there is significant potential for BioCorRx's products, which address a multi-billion dollar, underserved market with few viable options for patients, to be a real game changer in the field of addiction treatment. For this reason, I have decided to dedicate more time than previously anticipated and I'm grateful for the opportunity to help with their mission."
About BioCorRx
BioCorRx Inc. (OTC PINK: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product (s). For more information on BICX, visit www.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
nrudman@crescendo-ir.com
SOURCE: BioCorRx Inc.
XLI Technologies, Inc. is Not Going Out of Business
Feb 17, 2017 06:00:00 (ET)
XLI Technologies, Inc. is Not Going Out of Business
LAS VEGAS, Feb. 17, 2017 (GLOBE NEWSWIRE) -- XLI Technologies, Inc. (OTC PINK:XLIT) ("XLI" or the "Company") is pleased to provide current updates, adjustments and direction regarding its corporate position, status and adjusted business development plan.
XLI is currently preparing to file a formal complaint to the SEC regarding two parties in which they believe to be found causing financial damages, droit moral and affecting XLI's value in the marketplace. This caused the company not to be in current reporting status as well as having to extend the timeframe of all projections including, but not limited to, the theater rollout installations. These two parties are as follows: party #1, Traders-Choice (traders-choice.com). James Schramm stated "I, XLI and/or any/all related affiliates has never entertained, considered and/or conducted any business of any kind with Traders Choice." Party #2 is RDW Capital, LLC / John DeNobile. James Schramm commented, "RDW Capital, LLC and John DeNobile provided a convertible note to XLI in the beginning, positioning as to support the success of XLI. Their undermining and unimaginable plan caught me by surprise. I confronted John DeNobile on the phone with my findings and suspicions. I feel that his reaction was unprofessional to say the least. I feel that John threatened me, my family, XLI and the shareholders as his behavior and verbiage seemed as if he was a loanshark." Mr Schramm sent an email to John's / RDW's attorney, David E. Danovitch, Esq. regarding the issue. As James Schramm states, "My email to David was to allow an opportunity for clarity or a confirmation of my suspicions. My email was simple; reply back to set the record straight or do not reply back in which I will assume the confirmation of my suspicions." James Schramm never received a reply back from David E. Danovitch.
James Schramm, CEO of XLI Technologies, Inc., stated, "I am committed and still believe that XLI can be as successful as I felt in the beginning and possibly even more. I have no plans on XLI going out of business."
The company has committed to damage control, positioning to stabilize and to structure objectives that will ensure current reporting status and updated directions and positioning for the future. This process timeframe is estimated about 6 months to complete.
Despite James Schramm's financial losses and the current position of XLI, James decided again, to expense more of his own private time, money and resources to support a plan that will get the company back. Effective immediately, the following plan are several objectives that need to be met and completed: (XLI plans to release future PR providing details, specifics and status of each objective.)
* Updated Web Site ( XLItech.com ) COMPLETED
* Withdrawal of the Company's registration statement on Form S-1 (File No. 333-210562) COMPLETED
* Issue back 65 million common shares of James Schramm stock that he previously and voluntarily cancelled. COMPLETED
* Cancelling Caribbean Islands rights and get back/cancel 4.7 million shares of series C preferred stock. COMPLETED
* Facilitate a loan from a private investment fund to pay for the following: payoff and settle all convertible notes (no conversions), pay for "In House Legal (1 attorney), accounting and administration (1 exec.), Sales dept./facilitation/distribution opportunities (2 execs.), Pay expenses to bring company to current active reporting status.
* Complete/activate XLI off the pinks and on bulletin board (OTCQB).
* Complete the Theater rollout.
* Offering additional technology products and services which includes purchase and/or acquisitions of other companies. If and upon the possibility of acquiring other companies, XLI could possibly grow from a Technology company to an American Multinational Conglomerate Holding Company.
These positioning objectives can secure and insure a stable, successful and exciting company positioned for amazing growth.
Currently, XLI Technologies, Inc. provides unique, versatile, durable, and eco-friendly Nanotechnology printed light products (Printed LightSheets(TM)) to the entertainment sector including movie theaters, movie studios, production and distribution companies, talent and management agencies, marketing and PR firms, and outdoor media in the USA and Canada. Printed LightSheets(TM) are a 100% Nanotech-based light product utilizing a specialty coating printed on a thin sheet (as thin as paper) to generate a clean and pure light source that uses less than one watt of electricity per foot. Printed LightSheets can be bent, cut, folded and smashed without causing any affect or altering to the light. Printed LightSheets have a heat tolerance of 200 degrees F and cold tolerance of -15 degrees below zero, and can stay on continuously for over 10 years. This Printed LightSheet does not have or use any LEDs, bulbs, fuses, glass, and not even any conductive metal.
Notice Regarding Forward-Looking Statements
This press release contains "forward-looking statements," as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release, which are not purely historical, are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with intellectual property protection, marketing and sale, manufacturing and distribution and difficulties associated with obtaining financing on acceptable terms. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that the beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our most recent annual report for our last fiscal year, our quarterly reports, and other periodic reports filed from time-to-time with the Securities and Exchange Commission.
Contact: Info@XLItech.com
(MORE TO FOLLOW) Dow Jones Newswires
February 17, 2017 06:00 ET (11:00 GMT)
I have etrade too !! how can I access level 2 ? steps ?
PPS Adjustment day ?
BioCorRx (BICX) Update: FDA Results Imminent
New York, NY, February 13, 2017 --(PR.com)-- JGR Capital Partners, a leading equity research and digital investor relations firm, has announced it has released an update on BioCorRx (OTC PINK: BICX).
The full report can be found at www.jgrcapitalpartners.com
BioCorRx working with Innovative Science Solutions for regulatory matters
BioCorRx Inc. announced on January 12th 2017, that it would be working with Innovative Science Solutions to assist the company with regulatory matters for the release of its Naltrexone injectable product BIXC101 and one or more other naltrexone formularies. BICX101 is currently in preclinical development under BioCorRx's pharmaceutical subsidiary, in partnership with TheraKine. The founder of ISS and Head of Clinical and Regulatory Support, Dr. Steven M. Weisman, will play an important role in assisting the company with FDA 505(b)(2) regulatory submissions. Rather than taking a longer route to approval using the traditional New Drug Applications process by the FDA, the Company will use the abbreviated 505(b)(2), which will cut down time and the cost in marketing efforts. Dr. Weisman has managed all aspects of the FDA advisory committee process for many large pharmaceutical companies over the world with over 20 years of expertise in pharmacology, toxicology and product development.
Covance preclinical results imminent
Another operational development that is of importance for BioCorRx is the results of the Covance preclinical-study that started on December 22, 2016 and is expected to be completed within the next few weeks. BioCorRx is planning to request a pre-IND meeting with the FDA within the next few weeks.
Positive developments with Alpine Creek Capital
BioCorRx is also in talks with private equity firm Alpine Creek Capital to restructure its current $2.5 million investment from a derivative instrument into shares which will greatly improve the company's capital structure. Alpine Creek Capital is also in talks to invest an additional $2.5 Million, for a total of $5 million in invested capital.
Drug Free Anaheim is great initiative for company
BioCorRx, Inc. and Anaheim Mayor, Tom Tait, have struck up a partnership to assist in the city's new program called "Drug Free Anaheim," which will help drug addicts receive the rehabilitation services that they need instead of taking measures to prosecute and incarcerate them. The program encourages chronic drug users to walk into a police station in Anaheim, CA and ask for help - in which case they will be taken to a rehabilitation center. The full transcript of the Mayor's address can be found at http://anaheim.net/367/state-ofthe-city
Disclosures pertaining to this report can be found at www.jgrcapitalpartners.com.
About BioCorRx Inc:
BioCorRx is an addiction treatment company offering a unique approach to substance abuse. The BioCorRx Recovery Program is a non-addictive medication-assisted program consisting of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers non-addictive medication Naltrexone, an opioid antagonist that can significantly reduce cravings for opioids and alcohol. The second component developed by the company is a one-on-one proprietary counseling program specifically tailored for treating alcoholism and substance abuse disorders. More information on BioCorRx can be found at www.biocorrx.com.
About JGR Capital Partners:
JGR Capital Partners is an international equity research and digital investor relations firm that focuses on companies under $2 billion in market capitalization. The firm is headquartered in New York City, with affiliate offices in Los Angeles, Sao Paulo, and Shanghai. Our team of experienced analysts form investment theses based on company and sector expertise, with a strict focus on fundamentals and valuation. For more information on JGR Capital Partners, visit our website at www.jgrcapitalpartners.com.
Contact Information:
Jordan Ring
646-862-2854
Contact via Email
http://www.jgrcapitalpartners.com/
Read the full story here: http://www.pr.com/press-release/705330
Investor Relations:
Crescendo Communications, LLC
(212) 671-1020 x304
nrudman@crescendo-ir.com
Pip !!!! 0.10 got hit :)
On www.Pharmacychoice.com
http://www.pharmacychoice.com/news/article.cfm?Article_ID=1693164
0.09 got hit !!!!! GO BICX
0.09 on the ASK ;)
Well !! I am glad I missed it ! remember DREAM BIG :))
this is Awesome Pip !!
by the way , 0.64 got hit :)
Some REAL good buying flowing in as we speak !!
That's a lot of hitting !
Hey ALL !! someone from this board is buying or we have new investors ?
Hopefully it's not the TITANIC :)
One Good / Solid NEWS and BICX will be above 0.50 PPS